menu

Ultra-Long-Acting Insulins: The Future of Insulin Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Ultra-Long-Acting Insulins:
The Future of Insulin Therapy

5 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Are Ultra-Long-Acting Insulins the future of diabetes therapy? Will they prevent therapeutic inertia and increase adherence by patients? How will they relieve the treatment burden for people living with Type 2 diabetes?

  • Disclosure of Conflicts of Interest

    Primary Care Education Consortium adheres to the conflict-of-interest policy of the ACCME and the AMA. All individuals in a position to control the content disclose any relationships they may have with commercial companies whose products or services may be mentioned so that participants may evaluate the objectivity of the presentations. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed by the faculty. Only participants who have no conflict of interest or who agree to an identified mitigation process prior to their participation were involved in the CME activity.

    Dr. Goldenberg discloses that he serves as a consultant, speaker, and/or receives research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Novo Nordisk and Sanofi.

    Dr. Frias discloses that he serves as a consultant and/or speaker for Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer and Sanofi. He also receives research support from Akero, AstraZeneca, Boehringer Ingelheim, BMS, 89bio, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel and Sanofi.

    Dr. Mathieu serves or has received research support from and/or has served on the advisory panel and/or speakers bureau for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, AstraZeneca, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz, Novartis, and Vertex. Financial compensation for these activities has been received by KU Leuven. She is president of the European Association for the Study of Diabetes which receives support from Eli Lilly and Company, Merck Sharpe & Dohme, Novo Nordisk A/S, Novo Nordisk Foundation, Sanofi, Boehringer Ingelheim, and the Japanese Diabetes Society.

    All relevant financial relationships have been mitigated.

  • Target Audience

    The target audience for this activity includes diabetologists/endocrinologists, primary care physicians, and other healthcare professionals outside of the United States and the United Kingdom who treat patients living with diabetes. The intent is to deliver content from the US-based ADA meeting to those in other countries who are unable to attend in person.

  • Learning Objectives

    1. Assess barriers and limitations of currently available insulin regimens and describe how Ultra-Long-Acting Insulins may overcome therapeutic inertia and improve adherence to therapy.
    2. Compare outcomes and safety of Ultra-Long-Acting Insulins versus current long-acting basal insulins as assessed by published clinical trials.
    3. Discuss the outlook for Ultra-Long-Acting Insulins as therapy for managing type 2 diabetes.
  • Accreditation and Credit Designation Statements

    Primary Care Education Consortium is accredited by the ACCME to provide continuing medical education for physicians.

    Primary Care Education Consortium designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    All other healthcare professionals completing this course will be issued a statement of participation.

    Credit is available from July 10, 2023 to July 9, 2024. 

  • Disclaimer

    This CME activity includes discussion about medications not yet approved.

  • Provider(s)/Educational Partner(s)

       

  • Commercial Support

    Supported by an independent medical education grant from Novo Nordisk A/S.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Are Ultra-Long-Acting Insulins the future of diabetes therapy? Will they prevent therapeutic inertia and increase adherence by patients? How will they relieve the treatment burden for people living with Type 2 diabetes?

  • Disclosure of Conflicts of Interest

    Primary Care Education Consortium adheres to the conflict-of-interest policy of the ACCME and the AMA. All individuals in a position to control the content disclose any relationships they may have with commercial companies whose products or services may be mentioned so that participants may evaluate the objectivity of the presentations. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed by the faculty. Only participants who have no conflict of interest or who agree to an identified mitigation process prior to their participation were involved in the CME activity.

    Dr. Goldenberg discloses that he serves as a consultant, speaker, and/or receives research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Novo Nordisk and Sanofi.

    Dr. Frias discloses that he serves as a consultant and/or speaker for Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer and Sanofi. He also receives research support from Akero, AstraZeneca, Boehringer Ingelheim, BMS, 89bio, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel and Sanofi.

    Dr. Mathieu serves or has received research support from and/or has served on the advisory panel and/or speakers bureau for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, AstraZeneca, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz, Novartis, and Vertex. Financial compensation for these activities has been received by KU Leuven. She is president of the European Association for the Study of Diabetes which receives support from Eli Lilly and Company, Merck Sharpe & Dohme, Novo Nordisk A/S, Novo Nordisk Foundation, Sanofi, Boehringer Ingelheim, and the Japanese Diabetes Society.

    All relevant financial relationships have been mitigated.

  • Target Audience

    The target audience for this activity includes diabetologists/endocrinologists, primary care physicians, and other healthcare professionals outside of the United States and the United Kingdom who treat patients living with diabetes. The intent is to deliver content from the US-based ADA meeting to those in other countries who are unable to attend in person.

  • Learning Objectives

    1. Assess barriers and limitations of currently available insulin regimens and describe how Ultra-Long-Acting Insulins may overcome therapeutic inertia and improve adherence to therapy.
    2. Compare outcomes and safety of Ultra-Long-Acting Insulins versus current long-acting basal insulins as assessed by published clinical trials.
    3. Discuss the outlook for Ultra-Long-Acting Insulins as therapy for managing type 2 diabetes.
  • Accreditation and Credit Designation Statements

    Primary Care Education Consortium is accredited by the ACCME to provide continuing medical education for physicians.

    Primary Care Education Consortium designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    All other healthcare professionals completing this course will be issued a statement of participation.

    Credit is available from July 10, 2023 to July 9, 2024. 

  • Disclaimer

    This CME activity includes discussion about medications not yet approved.

  • Provider(s)/Educational Partner(s)

       

  • Commercial Support

    Supported by an independent medical education grant from Novo Nordisk A/S.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Jul 2024